- Home
- SXTC vs PRFX Comparison
SXTC vs PRFX Comparison
Compare SXTC & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTC | PRFX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.6M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SXTC | PRFX |
|---|---|---|
| Price | $2.10 | $2.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.2K | ★ 327.2K |
| Earning Date | 08-19-2019 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.58 |
| 52 Week High | $6.98 | $3.71 |
Technical Indicators
Market Signals| Indicator | SXTC | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 44.04 |
| Support Level | $1.88 | $1.29 |
| Resistance Level | $2.16 | $2.89 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 37.18 | 26.39 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.